Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

20182,753 citationsJournal Articlebronze Open Access

Authors

Scott Antonia · Florida Hospital Cancer Institute

Augusto Villegas · Florida Hospital Cancer Institute

Davey B. Daniel · Florida Hospital Cancer Institute

David Vicente · Florida Hospital Cancer Institute

Shuji Murakami · Florida Hospital Cancer Institute

Rina Hui · Florida Hospital Cancer Institute

Takayasu Kurata

Abstract

Durvalumab therapy resulted in significantly longer overall survival than placebo. No new safety signals were identified. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).

Topics & Keywords

Colorectal and Anal Carcinomas Gastric Cancer Management and Outcomes Hepatocellular Carcinoma Treatment and Prognosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 379, Issue 24, pp. 2342-2350

DOI: 10.1056/nejmoa1809697

Field-Weighted Citation Impact: 336.42